Immunovive
About Immunovive
Immunovive provides a fee-for-service antibody discovery platform that generates high-affinity monoclonal hybridomas from in vivo sources within six weeks, enabling rapid access to diverse antibody candidates. This service addresses the challenges of lengthy discovery timelines and intellectual property constraints, allowing clients to retain full rights to the resulting antibodies for downstream drug development.
```xml <problem> Traditional antibody discovery methods can be slow, expensive, and encumbered by intellectual property restrictions, hindering rapid development of novel biotherapeutics. Many researchers face challenges in accessing diverse antibody candidates quickly and retaining full rights for downstream drug development. </problem> <solution> Immunovive offers a fee-for-service antibody discovery platform, BinderGen™, that delivers high-affinity monoclonal hybridomas derived from in vivo sources within six weeks. The platform employs robust immunization protocols and efficient recovery of rare binders, optimized for hit retention and native VH-VL pairing. Clients retain 100% ownership of the resulting antibodies, facilitating downstream applications such as target validation, proof-of-concept studies, lead optimization, and multimodality engineering. The service provides drug-like protein deliverables, accelerating biotherapeutics discovery by eliminating access barriers and IP encumbrances. </solution> <features> - Rapid in vivo antibody discovery platform delivering monoclonal hybridomas in 6 weeks - Robust immunization protocols for diverse antibody generation - Efficient recovery of rare binders with optimized hit retention - Native VH-VL pairing to maintain antibody integrity - Drug-like protein deliverables suitable for therapeutic development - Fee-for-service model with no intellectual property restrictions </features> <target_audience> The primary customers are biotherapeutic investigators and researchers in the life science industry seeking rapid access to diverse, high-affinity antibodies for drug development applications. </target_audience> <revenue_model> Immunovive operates on a fee-for-service model, charging clients for each antibody discovery project completed using the BinderGen™ platform. </revenue_model> ```
What does Immunovive do?
Immunovive provides a fee-for-service antibody discovery platform that generates high-affinity monoclonal hybridomas from in vivo sources within six weeks, enabling rapid access to diverse antibody candidates. This service addresses the challenges of lengthy discovery timelines and intellectual property constraints, allowing clients to retain full rights to the resulting antibodies for downstream drug development.
Where is Immunovive located?
Immunovive is based in Boston, United States.
When was Immunovive founded?
Immunovive was founded in 2023.
- Location
- Boston, United States
- Founded
- 2023
- Employees
- 3 employees